WO2005062871A3 - Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays - Google Patents

Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays Download PDF

Info

Publication number
WO2005062871A3
WO2005062871A3 PCT/US2004/043022 US2004043022W WO2005062871A3 WO 2005062871 A3 WO2005062871 A3 WO 2005062871A3 US 2004043022 W US2004043022 W US 2004043022W WO 2005062871 A3 WO2005062871 A3 WO 2005062871A3
Authority
WO
WIPO (PCT)
Prior art keywords
tat
assays
linear epitope
recombinant
conjugates
Prior art date
Application number
PCT/US2004/043022
Other languages
French (fr)
Other versions
WO2005062871A2 (en
Inventor
C David Pauza
Ilia Tikhonov
Tracy Jean Ruckwardt
Glen Scot Hatfield
Original Assignee
Univ Maryland Biotech Inst
C David Pauza
Ilia Tikhonov
Tracy Jean Ruckwardt
Glen Scot Hatfield
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland Biotech Inst, C David Pauza, Ilia Tikhonov, Tracy Jean Ruckwardt, Glen Scot Hatfield filed Critical Univ Maryland Biotech Inst
Publication of WO2005062871A2 publication Critical patent/WO2005062871A2/en
Publication of WO2005062871A3 publication Critical patent/WO2005062871A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
    • C07K16/1072—Regulatory proteins, e.g. tat, rev, vpt
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to compositions and methods for eliciting a neutralizing antibody response specific to HIV Tat proteins. Also disclosed are vaccines including amino terminus Tat linear epitope peptide fragments having the amino terminus sequence of the HIV Tat protein, conjugated to HIV viral Gag protein. The invention relates as well to the nucleotide sequences encoding the peptide fragments, recombinant vectors carrying the sequences, recombinant host cells including either the sequences or vectors, and recombinant peptides. The invention further includes methods for using the isolated, recombinant peptides in vaccines, assays, and for use in therapeutic applications.
PCT/US2004/043022 2003-12-19 2004-12-20 Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays WO2005062871A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US53152903P 2003-12-19 2003-12-19
US60/531,529 2003-12-19

Publications (2)

Publication Number Publication Date
WO2005062871A2 WO2005062871A2 (en) 2005-07-14
WO2005062871A3 true WO2005062871A3 (en) 2006-04-06

Family

ID=34738661

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/043022 WO2005062871A2 (en) 2003-12-19 2004-12-20 Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays

Country Status (1)

Country Link
WO (1) WO2005062871A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006214563B2 (en) 2005-02-15 2011-08-18 Thymon, L.L.C. Methods and compositions for impairing multiplication of HIV-1
CN111153996B (en) * 2020-01-10 2021-12-14 苏州睿瀛生物技术有限公司 Antibody of G protein coupled receptor, preparation method thereof and G protein coupled receptor kit

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580773A (en) * 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US20030223964A1 (en) * 1998-12-31 2003-12-04 Susan Barnett Expression of HIV polypeptides and production of virus-like particles

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580773A (en) * 1992-06-17 1996-12-03 Korea Green Cross Corporation Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV)
US5891994A (en) * 1997-07-11 1999-04-06 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US6193981B1 (en) * 1997-07-11 2001-02-27 Thymon L.L.C. Methods and compositions for impairing multiplication of HIV-1
US20030223964A1 (en) * 1998-12-31 2003-12-04 Susan Barnett Expression of HIV polypeptides and production of virus-like particles

Also Published As

Publication number Publication date
WO2005062871A2 (en) 2005-07-14

Similar Documents

Publication Publication Date Title
WO2003070760A3 (en) Anti-amyloid beta antibodies and their use
WO2007106476A3 (en) Compositions and methods for enhancing the immunogenicity of antigens
MX348154B (en) IL-1ß BINDING ANTIBODIES AND FRAGMENTS THEREOF.
WO2005086794A3 (en) Lactobacillus acidophilus nucleic acid sequences encoding stress-related proteins and uses therefor
DK1278534T3 (en) Methods and compositions for attenuating the multiplication of HIV-1
WO2002070652A3 (en) Novel molecules of the card-related protein family and uses thereof
WO2001066778A3 (en) Production of foreign polypeptides in plants as viral coat protein fusions
WO2006127822A3 (en) Scytovirin domain 1 related polypeptides
PT1417222E (en) Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope
DE69935599D1 (en) MODIFIED HCV PEPTIDE VACCINES
WO2004056316A3 (en) Vaccines against hiv-1 tat protein to generate neutralizing antibodies
WO2005062871A3 (en) Tat linear epitope peptides and conjugates thereof for use in therapeutic compositions and assays
CA2338886A1 (en) Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response
WO2001061005A3 (en) Molecules of the pyrin domain protein family and uses thereof
WO2003035892A3 (en) Novel methods for introducing molecules into cells and vectors and compositions for use in such methods
WO2004087886A3 (en) Modified adenoviral e1a constructs and methods of use thereof
WO2001077151A3 (en) Fdrg proteins and nucleic acid molecules and uses therefor
WO2002051237A3 (en) Helicobacter proteins, nucleic acids and uses thereof
WO2002018426A3 (en) Rabbit hemorrhagic disease vaccine and antigens
WO2004092195A3 (en) Dendritic cell binding proteins and uses thereof
WO2005058944A3 (en) Immunogenic peptides fragments of xage-1
AR017709A1 (en) ISOLATED POLINUCLEOTIDE MOLECULA, RECOMBINING VECTOR, RECOMBINANT HOSPEDING CELL, SUBSTANTIALLY PURIFIED PROTEIN, POLYPEPTIDOSUSTANTIALLY PURIFIED, PEPTIDIC FRAGMENT, ANTIBODY, TIMED CELLULATED CELLULATED MODEL, MODELED TIME
WO2002012475A3 (en) C1q-related factor, homologous polypeptides and therapeutic uses thereof
WO2000058438A3 (en) Conformationally constrained peptides
WO2001059065A3 (en) Novel molecules of the card-related protein family and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)